/TYRA
TYRA Stock - Tyra Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$25.51+10.96%
+$2.52 (+10.96%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+45.0%upside
Target: $36.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TYRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$25.25 – $25.77
TARGET (TP)$37.00
STOP LOSS$23.47
RISK/REWARD1:5.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.09
52W High$25.88
52W Low$6.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-47,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-104,177,000 | $-79,945,000 | $-58,927,000 | $-26,288,000 | $-9,297,000 |
| Net Income | $-86,481,000 | $-69,134,000 | $-55,325,000 | $-26,294,000 | $-9,314,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.51 | $-1.62 | $-1.23 | $-0.63 | $-0.22 |
Company Overview
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Visit WebsiteRating Distribution
Strong Buy
1
14%
Buy / Outperform
5
71%
Hold / Neutral
1
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish1 Neutral/Bearish
Price Targets
$26
Average Target
↑ 0.6% Upside
Now
$12
Low
$26
Average
$35
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 3rd 2025 | Raymond James | Initiation | Strong Buy | $35 |
| May 21st 2025 | Piper Sandler | Resumed | Overweight | $33 |
| January 7th 2025 | UBS | Initiation | Buy | $28 |
| October 18th 2024 | BofA Securities | Upgrade | Buy | $31← $22 |
| August 15th 2024 | Piper Sandler | Initiation | Overweight | $33 |
| December 15th 2023 | BofA Securities | Downgrade | Neutral | $15← $25 |
| June 30th 2023 | Wedbush | Initiation | Outperform | $27 |
| February 3rd 2023 | Oppenheimer | Initiation | Outperform | $17 |
| June 23rd 2022 | H.C. Wainwright | Initiation | Buy | $12 |
Earnings History & Surprises
TYRABeat Rate
53%
Last 17 quarters
Avg Surprise
-9.5%
EPS vs Estimate
Beats / Misses
9/7
1 met exactly
Latest EPS
$-0.50
Q4 2025
EPS Surprise History
Q1 24
-10.4%
$-0.53vs$-0.48
Q2 24
+23.9%
$-0.35vs$-0.46
Q3 24
+22.0%
$-0.32vs$-0.41
Q4 24
-2.5%
$-0.41vs$-0.40
Q1 25
+10.4%
$-0.43vs$-0.48
Q2 25
+4.1%
$-0.47vs$-0.49
Q3 25
+11.3%
$-0.47vs$-0.53
Q4 25
0.0%
$-0.50vs$-0.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.54 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.50 | $-0.50 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.53 | $-0.47 | +11.3% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.49 | $-0.47 | +4.1% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.48 | $-0.43 | +10.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.40 | $-0.41 | -2.5% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.41 | $-0.32 | +22.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.46 | $-0.35 | +23.9% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-0.48 | $-0.53 | -10.4% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.35 | $-0.49 | -40.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.34 | $-0.31 | +8.8% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.37 | $-0.28 | +24.3% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.35 | $-0.31 | +11.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.41 | $-0.30 | +26.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.33 | $-0.36 | -9.1% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.20 | $-0.36 | -80.0% | ✗ MISS |
Q1 2022 | Mar 3, 2022 | $-0.21 | $-0.24 | -14.3% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.29 | $-0.72 | -148.3% | ✗ MISS |
Q3 2021 | Sep 15, 2021 | — | $-0.19 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.15 | — | — |
Latest News
Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $37
📈 PositiveBenzinga•Dec 16, 2025, 12:36 PM
Tyra Biosciences Appoints Bhavesh Ashar As COO
➖ NeutralBenzinga•Dec 1, 2025, 01:08 PM
Tyra Biosciences Q3 EPS $(0.50), Inline
➖ NeutralBenzinga•Nov 5, 2025, 09:48 PM
Raymond James Initiates Coverage On Tyra Biosciences with Strong Buy Rating, Announces Price Target of $35
📈 PositiveBenzinga•Sep 3, 2025, 04:54 PM
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target
📈 PositiveBenzinga•Aug 22, 2025, 10:58 AM
Tyra Biosciences shares are trading higher after the company announced it has dosed its first child in its Phase 2 trial of Dabogratinib.
📈 PositiveBenzinga•Aug 21, 2025, 03:51 PM
Tyra Biosciences Doses First Child In Phase 2 Trial Of Dabogratinib, First Oral FGFR3 Inhibitor For Achondroplasia
📈 PositiveBenzinga•Aug 21, 2025, 12:12 PM
Tyra Biosciences Narrows Loss in Q2
📈 PositiveThe Motley Fool•Aug 14, 2025, 09:17 PM
Frequently Asked Questions about TYRA
What is TYRA's current stock price?
Tyra Biosciences, Inc. (TYRA) is currently trading at $25.51 per share. The stock has moved +10.96% today.
What is the analyst price target for TYRA?
The average analyst price target for TYRA is $37.00, based on 1 analyst.
What sector is Tyra Biosciences, Inc. in?
Tyra Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TYRA's market cap?
Tyra Biosciences, Inc. has a market capitalization of $1.36 billion, making it a small-cap company.
Does TYRA pay dividends?
No, Tyra Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
Explore stocks similar to TYRA for comparison